Compare BridgeBio Pharma Inc (BBIO) vs ProShares Ultra Bloomberg Natural Gas ETF (BOIL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ProShares Ultra Bloomberg Natural Gas ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while ProShares Ultra Bloomberg Natural Gas ETF trades at $20.87. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares Ultra Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | BOIL | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $87.24 |
52-Week Low | $47.29 | $18.74 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BOIL trades at $19.12, up 2.03% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock faces resistance near $20 and support at $18. Recent news highlights natural gas market volatility and company-specific updates, including an investor webcast and annual meeting results. Financial ratios are unavailable, limiting fundamental assessment.
The outlook remains cautious due to bearish technicals and reliance on natural gas price swings. Risks include energy market fluctuations and competitive pressures. Analyst sentiment is mixed, with some viewing BOIL as a tactical tool amid volatility, but the lack of fundamental data warrants careful evaluation for long-term investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ProShares Ultra Bloomberg Natural Gas ETF
BOIL is a leveraged ETF that seeks to provide two times (2x) the daily performance of the Bloomberg Natural Gas Subindex. It uses futures contracts to offer magnified exposure to natural gas price movements.
Read more on BOIL →
